1. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Issue 10265 (5th December 2020) Authors: Cortes, Javier; Cescon, David W; Rugo, Hope S; Nowecki, Zbigniew; Im, Seock-Ah; Yusof, Mastura Md; Gallardo, Carlos; Lipatov, Oleg; Barrios, Carlos H; Holgado, Esther; Iwata, Hiroji; Masuda, Norikazu; Otero, Marco Torregroza; Gokmen, Erhan; Loi, Sherene; Guo, Zifang; Zhao, Jing; Aktan, Gursel; Ka... Journal: Lancet Issue: Volume 396:Issue 10265(2020) Page Start: 1817 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗